Clinical Trial Update: Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating dasatinib for recurrent or metastatic malignant salivary gland tumors has completed, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma
• Salivary Gland Cancer

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2015-04-03